managing patients with t-all who relapse or are refractory to first-line treatment
Published 2 years ago • 210 plays • Length 0:48Download video MP4
Download video MP3
Similar videos
-
1:08
unmet needs in t-all: targeted therapies & managing relapse
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
1:56
treatment selection & sequencing in patients with relapsed, intolerant, or refractory myeloma
-
1:38
future treatment strategies for r/r ph all
-
2:31
mrd-oriented trials for patients with relapsed t-all
-
2:06
managing relapsed all: the role of novel cellular therapies & importance of conditioning regimens
-
1:53
factors to consider for the optimal management of relapse in multiple myeloma
-
7:43
exploring a therapy called jakafi® (ruxolitinib)
-
9:25
mgus diagnosis: a step-by-step approach
-
3:37
is remote monitoring for crs in the future? | sridevi rajeeve, md | ash 2021
-
0:48
asciminib for the treatment of cml
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
2:45
continuity of care for patients with hematological predispositions to aml
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:08
the potential of tcrs for relapse management
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
0:42
the importance of genomic characterization in t-all
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml